To explore whether inhibition of FGFR2 affects the potential downstream YAP1 signaling in GC, AGS and MGC-803 were treated with a pan-FGFR inhibitor AZD4547, which is highly sensitive to FGFR2. Here, YAP1 is linked to gastric cancer.